

NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 million forecast and analyst Buy...
You can purchase shares of NeuroSense Therapeutics (NASDAQ:NRSN) through any online brokerage.
Other companies in NeuroSense Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
NeuroSense Therapeutics has a consensus price target of $170.00.
The stock price for NeuroSense Therapeutics (NASDAQ: NRSN) is $1.57 last updated November 6, 2026 at 4:27 PM EST.
There are no upcoming dividends for NeuroSense Therapeutics.
NeuroSense Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for NeuroSense Therapeutics.
NeuroSense Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS,...